

45TH ANNUAL CONGRESS

INSTITUTO DE HIGIENE E MEDICINA TROPICAL LISBON 22-25 JUNE 2025

PROGRAMME

Sunday 22 June

14:00-15:00	Registration
15:00-15:45	Industry Sponsored Symposium Chairs: Bernd Merkl, Troels Lillebaek
	15:00 Inna Friesen, Borstel, Germany Redefining the diagnosis of drug-resistant TB: Clinical validation of FluoroType® MTBDR VER2.0 and first results of tNGS workflow integration.
15:45-16:30	Coffee Break
16:30-19:00	Opening Session Chairs: Troels Lillebaek, Miguel Viveiros, Raquel Duarte 16:30 Welcome words, ESM and Congress Presidents Troels Lillebaek – President of European Society of Mycobacteriology ESM Miguel Viveiros – Chair of ESM 2025 and Deputy Director of IHMT NOVA
	Fernando de Almeida – President of the National Institute of Health Dr. Ricardo Jorge Filipe Froes – Vice-President of the Portuguese Society of Pneumonology Rita Sá Machado – Portuguese General Director of Health
	Opening Keynote 17:00 Raquel Duarte, University of Porto GL01 Challenges in Tuberculosis Management Today
	17:45 Gertrud Meissner Award presented by S. Niemann
	18:10 GL02 Gardner Middlebrook Award
19:00-21:30	Networking drinks and light dinner snacks at the Institute of Hygiene and Tropical Medicine



Monday 23 June

08:00-08:30	Registration
08:30-10:00	Session 1: Molecular Biology and Mycobacterial Evolution
	The evolutionary history and phylogeny of mycobacteria, along with genomics for tracking transmission, resistance, and the evolution of drug resistance mechanisms provide comprehensive insights into their biology and adaptation.
	Chairs: Christophe Sola, João Perdigão
	08:30 Roland Brosch, Institut Pasteur, Paris GL03 The Evolutionary History and Phylogeny of Mycobacteria
	09:00 Dmytro Butov, Kharkiv National Medical University, Kharkiv, Ukraine OR01 Molecular Epidemiology of Tuberculosis in Ukraine: A Nationwide Whole-Genome Sequencing Study (2020–2023)
	09:15 Arash Ghodousi, Vita-Salute San Raffaele University, Milan OR02 CRISPR and phage footprints reveal an aquatic ancestry for the tuberculosis pathogen
	09:30 Faramarz Valafar, San Diego State University OR03 Interred mechanisms of resistance and host immune evasion revealed through network-connectivity analysis of M. tuberculosis complex graph pangenome
	09:45 Nour Gharbi, EPHE, PSL University, Paris OR04 Genome-wide association analysis of Mycobacterium tuberculosis lineage 2 reveals key factors for its enhanced epidemic success
10:00-10:30	Coffee Break
10:30-12:00	Session 2: One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease
	The impact of aging, chronic diseases, co-infections, climate change, water quality, and microbiota on M. tuberculosis and non-tuberculous mycobacterial infections, as well as zoonotic tuberculosis in the One Health Era, highlights the need for an integrated approach addressing human, animal, and environmental health to prevent mycobacterial infection and transmission
	Chairs: Nuno Empadinhas, Leen Rigouts
	10:30 Jean-François Guégan, <i>UMR MIVEGEC, Montpellier, France</i> GL04 Canonical fact versus hypothesis testing to decipher transmission of non-tuberculous and tuberculous mycobacteria
	11:00 Camille Allam, Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux (CNR MyrMA) OR05 Standardised protocol for the detection and quantification of nontuberculous mycobacteria in tap water and its application in investigating the source of clinical infections
	11:15 Margo Diricks, Research Center Borstel OR06 Indoor water systems as reservoirs for clinically relevant non-tuberculous mycobacteria in Germany
	11:30 Anita Michel, <i>University of Pretoria</i> OR07 TB through a One Health lens: Challenges in a rural South African setting
	11:45 Xenia Emilie Iversen, Statens Serum Institute, Copenhagen OR08 Nontuberculous Mycobacteria in Denmark: Seven Decades of Clinical Occurrence



40-00 40-45	
12:00-12:45	Poster pitches - Session 1
	Chair: Leen Rigouts
	1 minute per poster
12:45-13:30	Lunch
13:30-14:45	Poster Session 1
	All posters with uneven numbers (P001, P003 etc)
14:45-16:15	Session 3: Host-Pathogen interactions in TB
	Advances in understanding the immune response to M. tuberculosis infection, including lineage-specific drivers of differential immune response and virulence, have highlighted biomarkers of protection and susceptibility as well as potential host-directed therapies.
	Chairs: Iñaki Comas, Margarida Saraiva
	14:45 Mireia Coscolla, <i>University of Valencia</i> GL05 Evolutionary insights in host-pathogen compatibility of M. tuberculosisecotypes.
	15:15 Javier Alonso del Real, Instituto de Biomedicina de Valencia - Spanish National
	Research Council OR09 Mycobacterium tuberculosis trehalose synthesis pathways as key determinant of tuberculosis disease progression
	15:30 Tobias Dallenga, Research Center Borstel OR10 Region-Specific Spatial Transcriptomics Reveal Distinct Immunological Functions in Human Tuberculosis Granulomas
	15:45 Jana Schoenfeld, Research Center Borstel OR11 Reprogramming of human macrophages in response to Mycobacterium tuberculosis complex (MTBC) infection
	16:00 Charlotte Genestet, International Center for Infectious Disease Research, Lyon OR12 Autologous host-pathogen pairing enhances early immune responses and bacterial control in tuberculosis ex vivo granuloma model
16:15-16:45	Coffee Break
16:45-18:15	Session 4: Clinical pathology and diagnostic advances
	Diagnostic advances, artificial intelligence and new technologies relevant to clinical pathologists and laboratory professionals.
	Chairs: Daniela Maria Cirillo, Rita Macedo
	16:45 Daniela Maria Cirillo, San Raffaele Hospital, Milan GL06 Co-development of new drugs and diagnostics to prevent drug resistance emergence
	17:15 Philip Fowler, University of Oxford OR13 Use of large-scale clinical samples to progressively create a reference catalogue of mycobacterial species
	17:30 Marcus May, Serum Life Science OR14 SIILTIBCY: A New Era in TB Diagnosis
	17:45 Noud Hermans, KNCV tuberculosis foundation, The Hague OR15 Genotypic drug susceptibility testing for new tuberculosis treatment regimens: The challenge of comprehensive and reliable WHO catalogue-based sequencing data interpretation



	18:00 Iñaki Comas, Instituto de Biomedicina de Valencia - Spanish National Research Council OR16 Complete genomes reveal unprecedented genomic diversity of Mycobacterium tuberculosis complex from global to within-host variation
18:30	Transfer to central Lisboa, for those booked on the guided tour
20:30	Traditional Dinner @ Museu da Cerveja Terreiro do Paço, Ala Nascente, nº 62 a 65 1100-148 Lisboa

Tuesday 24 June

08:30-09:00	Registration
09:00-10:00	Session 5: Recent advances in research on Mycobacterial pathogenesis Experimental infection models, ranging from vertebrates, rodents, and non-human primates to novel in vitro systems such as human granulomas, organoids, and lung-on-achip.
	Chairs: Mireia Coscolla, Maria Salomé Gomes
	09:00 William Branchett, Francis Crick Institute, London GL07 Models and Mechanisms of M. tuberculosis Infection Outcome
	09:30 Mariona Cortacans, Institut d'investigació en Ciències de la Salut Germans Trias i Pujol, Badalona OR17 When Non-Pathogens Kill: Mycolicibacterium manresensis as a Model for Cryptic Virulence in Mycobacteria
	09:45 Marta Arch, Institut d'investigació en Ciències de la Salut Germans Trias i Pujol, Badalona OR18 Investigating the virulence of Mycobacterium abscessus using the Drosophila melanogaster infection model
10:00-10:25	Poster pitches - Session 2
	Chair: Mireia Coscolla
	1 minute per poster
10:25-11:00	Coffee Break
11:00-12:30	Session 6: New generation vaccines for TB and TB diagnostics
	Advances in vaccine research, including innovative adjuvants and strategies tailored to different epidemiological profiles driving the development of next-generation tuberculosis vaccines
	Chairs: Matthias Merker, Elsa Anes
	11:00 Helen McShane, University of Oxford GL08 Progress and challenges in tuberculosis vaccine development
	11:30 Patricia Cuenca Lara, CReSA, IRTA, Universitat Autònoma de Barcelona OR19 Evaluation of immune responses elicited by respiratory mucosal vaccination strategies against TB in a goat model



	11:45 Kristin Kremer, KNCV Tuberculosis Foundation, The Hague OR20 Utility of targeted Nanopore sequencing for the detection of drug-resistant tuberculosis in Kyrgyzstan
	12:00 Paulo Bettencourt, Faculty of Medicine, Universidade Católica Portuguesa, Rio de Mouro
	OR21 Immunopeptidomics for vaccines against tuberculosis
	12:15 Oren Tzfadia, Institute of Tropical Medicine, Antwerp OR22 Determining the genetic drivers of pathogenicity in the genus Mycobacterium
12:30-12:50	Poster pitches - Session 3
	Chair: Daniela Maria Cirillo
	1 minute per poster
12:50-13:45	Lunch
13:45-15:00	Poster Session 2
	All posters with an even number (P002, P004, etc)
15:00-15:45	Industry Sponsored Symposium
	Chairs: Matthias Merker, Erik Svensson
	15:00 Viktoria Szel, National Reference Laboratory for Mycobacteriology, Hungary Implementation plan of the Mycobacterium RealTime Kit Vircell (MRTVircell) Assay for Detecting Mycobacterium Species in National Mycobacterium Reference Lab, Hungary
15:45-16:15	Session 7: Therapeutic strategies for NTM and TB
	Treatment of NTM focused on evidence for new drugs, including antibiotic and non- antibiotic combinations, alongside discontinuation strategies and treatment adjustments based on clinical response.
	Chairs: Troels Lillebaek, Raquel Duarte
	15:45 Natalie Lorent, KU Leuven GL09 Rethinking NTM management: new drugs, new approaches, new hope.
16:15-16:45	Coffee Break
16:45-18:15	Session 8: Therapeutic strategies for NTM and TB Part 2
	Chairs: Daniela Maria Cirillo, Raquel Duarte
	16:45 Nicola Lorè, San Raffaele Scientific Institute, Milan OR23 Single-cell RNA sequencing shows that circulating monocytes enriched in IFN signaling are associated with nontuberculous mycobacteria pulmonary disease in cystic fibrosis
	17:00 D Moreira Sousa, Pulmonology Department, Local Health Unit Cova da Beira, Covilhã OR24 International Consensus Framework for Managing Treatment Failure in Nontuberculous Mycobacterial Pulmonary Disease
	17:15 Chloé Jacquet, Inserm U1070 PHAR2, Poitiers OR25 Fidaxomicin, a potential new drug for combinatorial therapies against Mycobacterium abscessus.



	17:30 Simone Mok, Irish Mycobacteria Reference Laboratory, St. James's Hospital, Dublin OR26 Evaluation of NTM-Profiler for identification and drug resistance prediction in nontuberculous mycobacteria from whole genome sequencing data
	17:45 Aarnoud van der Spoel, Dalhousie University, Halifax OR27 Modelling a genetic condition that protects against tuberculosis
	18:00 Fabio Saliu, San Raffaele Scientific Institute, Milan OR28 Preclinical murine models for studying lung infection and antimicrobial treatments of Nontuberculous mycobacteria
18:15	General Assembly
19:30	Social activity: Dinner and party @ Doca do Santo Armazém CP – Doca de Santo Amaro

Wednesday 25 June

08:30-09:00	Registration
09:00-11:00	Session 9: Neglected mycobacterial diseases – continuing challenges for a hopeful future
	New hurdles in the fight against neglected mycobacterial diseases such as leprosy and Buruli - resistance, challenges in diagnosis, and the debate between molecular and traditional methods to better identify these often non-cultivable pathogens.
	Chairs: Margarida Correia-Neves, Leen Rigouts
	09:00 Leen Rigouts, Institute of Tropical Medicine, Antwerp GL10 Neglected mycobacterial diseases - Continuing challenges for a hopeful future
	09:30 Emmanuelle Cambau, APHP-GHU Nord & Université Paris Cité GL11 Leprosy: back to the future
	10:00 Conor Meehan, Nottingham Trent University OR29 Validating a SNP calling pipeline for Mycobacterium leprae
	10:15 Louisa Warryn, Swiss Tropical and Public Health Institute OR30 The diagnostic potential of Mycobacterium ulcerans Mycolactone and the surface protein MUL_3720
	10:30 Alisa Aliaga Samanez, MIVEGEC (UMR Université de Montpellier, CNRS, IRD) OR31 Natural drivers and Human-Induced Pressures shaping the distribution of Mycobacterium ulcerans and Buruli Ulcer
	10:45 Tim Stinear, University of Melbourne OR32 Solving the transmission enigma of Buruli ulcer (Mycobacterium ulcerans infection)
11:00-11:30	Coffee Break



11:30-13:00

Session 10: Systems Biology Approaches to Accelerate Mycobacteriosis Drug Discovery

Emerging areas in the fight against TB and NTM including omics approaches for identifying new host and pathogen drug targets, advancements in drug delivery methods, drug discovery and repurposing pipelines for mycobacteriosis, exploration of non-antibiotic treatments, and innovations in adaptive clinical trial designs.

Chairs: Miguel Viveiros, Troels Lillebaek

11:30 Hannu Myllykallio, Polytechnique; Palaiseau

GL12 From Abyss to Mycobacterial Drug Discovery

12:00 **Pedro Duarte**, Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa

OR33 Implementing large-scale genomics and genomic subtractive strategies to expand the target space in Mycobacterium tuberculosis: a strategy for improving target-based drug discovery

12:15 Liliana Rodrigues, GHTM, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa

OR34 Exploring in silico drug repurposing to develop new therapeutic alternatives for tuberculosis

12:30 Andrea Muscetti, San Raffaele Scientific Institute, Milan

OR35 DprE1 inhibitors and bedaquiline combination for TB treatment: in-vitro and in-silico analyses

12:45 Salomé Gomes, University of Porto

OR36 Improved models for drug development against non-tuberculous mycobacteria

13:00-13:15

Poster Awards and Closing Ceremony

Chairs: Troels Lillebaek, Leen Rigouts



With thanks to our sponsors and partners

Platinum





Silver

















Supporters

